Literature DB >> 29579316

Obstacles to improving outcomes in the treatment of uveal melanoma.

Katy K Tsai1, Kathryn B Bollin2, Sapna P Patel3.   

Abstract

The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of specialty centers, and integrated multidisciplinary care between ophthalmology, radiation oncology, and medical oncology is far from the norm. This treatment isolation leads to limited communication about novel clinical trial opportunities. Clinical trials themselves are not widely available, and a lack of robust funding limits rapid and complete investigations. This review outlines the obstacles to success in uveal melanoma management and highlights strategies for overcoming these challenges. Cancer 2018;124:2693-2703.
© 2018 American Cancer Society. © 2018 American Cancer Society.

Entities:  

Keywords:  barriers; challenges; outcomes; success; therapy; treatment; trials; uveal melanoma

Mesh:

Substances:

Year:  2018        PMID: 29579316     DOI: 10.1002/cncr.31284

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Cordycepin (3'-Deoxyadenosine) Suppresses Heat Shock Protein 90 Function and Targets Tumor Growth in an Adenosine Deaminase-Dependent Manner.

Authors:  Su-Chan Lee; Lujain Alaali; HyukJean Kwon; Mohammed Rigi; Charles G Eberhart
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

2.  An insight into the molecular genetics of a uveal melanoma patient cohort.

Authors:  Susan Kennedy; Michael Rice; Sinead Toomey; Noel Horgan; Bryan T Hennessey; Annemarie Larkin
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

3.  Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma.

Authors:  Kartik Anand; Jason Roszik; Dan Gombos; Joshua Upshaw; Vanessa Sarli; Salyna Meas; Anthony Lucci; Carolyn Hall; Sapna Patel
Journal:  Cancers (Basel)       Date:  2019-06-20       Impact factor: 6.639

4.  Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer.

Authors:  Sophie Piperno-Neumann; Jose Maria Piulats; Matthias Goebeler; Iain Galloway; Iwona Lugowska; Jürgen C Becker; Pia Vihinen; Joachim Van Calster; Theodora Hadjistilianou; Rui Proença; Jose Maria Caminal; Muriel Rogasik; Jean-Yves Blay; Ellen Kapiteijn
Journal:  Cancers (Basel)       Date:  2019-06-13       Impact factor: 6.639

5.  KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma.

Authors:  Jingnan Zhang; Juan Zhang; Jing Guan; Lisha Yu; Shilong Yan
Journal:  Dis Markers       Date:  2022-08-21       Impact factor: 3.464

6.  Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.

Authors:  Meredith S Pelster; Stephen K Gruschkus; Roland Bassett; Dan S Gombos; Michael Shephard; Liberty Posada; Maura S Glover; Rinata Simien; Adi Diab; Patrick Hwu; Brett W Carter; Sapna P Patel
Journal:  J Clin Oncol       Date:  2020-10-30       Impact factor: 44.544

7.  Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.

Authors:  Prisca Bustamante; Denise Miyamoto; Alicia Goyeneche; Paulina García de Alba Graue; Eva Jin; Thupten Tsering; Ana Beatriz Dias; Miguel N Burnier; Julia V Burnier
Journal:  Cancer Med       Date:  2019-10-07       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.